CRSP - CRISPRセラピュ―ティクス (CRISPR Therapeutics AG) CRISPRセラピュ―ティクス



symbol CRSP
会社名 CRISPR Therapeutics AG (CRISPRセラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA) which is comprised of a crRNA component and a tracrRNA component either individually or combined together as a single guide RNA. The Company has business operations in London the United Kingdom as well as research and development operations in Cambridge the United States.   CRISPRセラピュ―ティクスはスイスのバイオ医薬品企業。ゲノム編集に従事し、遺伝子ベ―スの病気の治療に使用される「CRISPR/Cas9」プラットフォ―ムを開発する。スイス、米国、英国で事業を展開する。「CRISPR」ベ―スの開発をバイエルとバ―テックス・ファ―マシュ―ティカルズと協業する。本社はバ―ゼル。   CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
本社所在地 Baarerstrasse 14 Zug 6300 CHE
代表者氏名 Rodger Novak ロジャーノヴァク
代表者役職名 Chairman of the Board of Directors President Founder
電話番号 +41 41-561-3277
設立年月日 41548
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 127人
EBITDA EBITDA(百万ドル) -83.54900
終値(lastsale) 36.6
時価総額(marketcap) 1732197333.6
時価総額 時価総額(百万ドル) 1894.215
売上高 売上高(百万ドル) 37.15800
企業価値(EV) 企業価値(EV)(百万ドル) 1574.478
当期純利益 当期純利益(百万ドル) -84.94600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Crispr Therapeutics AG revenues decreased 61% to $2.4M. Net loss increased 52% to $66.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 31% to $37.1M (expense) Stock-based Compensation in R&D increase from $3.7M to $8.1M (expense).



   $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much  2022/05/02 21:04:56 Benzinga
CRISPR Therapeutics (NASDAQ: CRSP ) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a market capitalization of $4.02 billion. Buying $100 In CRSP: If … Full story available on
   What 4 Analyst Ratings Have To Say About CRISPR Therapeutics  2022/04/28 13:14:04 Benzinga
Within the last quarter, CRISPR Therapeutics (NASDAQ: CRSP ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 0 1 1 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, CRISPR Therapeutics has an average price target of $89.25 with a high of $120.00 and a low of $64.00. Below is a summary of how these 4 analysts rated CRISPR Therapeutics over the past 3 months. The … Full story available on
   Crispr Therapeutics: Progress, Risk, And Reward  2022/04/27 14:18:37 Seeking Alpha
CRISPR Therapeutics continues to make progress in all of its development platforms. See why I believe CRSP stock is a cautious buy for risk-tolerant investors.
   $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much  2022/04/20 16:48:52 Benzinga
CRISPR Therapeutics (NASDAQ: CRSP ) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a market capitalization of $4.51 billion. Buying $1000 In CRSP: If … Full story available on
   SPI, WDAY, CRSP and IMGN among after hour movers  2022/04/01 22:02:23 Seeking Alpha
Gainers: SPI Energy (SPI) +36%.Workday (WDAY) +11%.TMC the metals company (TMC) +10%.ThredUp (TDUP) +7%.WAVE Life Sciences (WVE) +4%.Losers: CRISPR Therapeutics (CRSP) -7%.ImmunoGen…
   Traynor Capital Management, Inc. Buys DoorDash Inc, Airbnb Inc, CRISPR Therapeutics AG, Sells ...  2021/07/21 20:38:07 GuruFocus
Related Stocks: IJH , CRSP , BA , IJR , PLTR , DFEN , DASH , ABNB , FNCL , QDEL , ISRG , TLRY , ATOM , GME , BE , ARKK , NQP , CGC ,
   Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending (MRTX, BPMC, ARNA, TBIO, SRPT, INCY, SPLK, PXD, NTNX, BRBR, SMPL, CLR, ARVN, RLAY, QURE, CRSP, ALLO, ALLK, KRTX)  2021/07/20 08:30:00 Business Insider
Summary List Placement According to data from Goldman Sachs, 2021 has been a record year for mergers and acquisitions (M&A) activity. The investment bank says M&A volume has already hit $1.9 trillion this year, marking a multi-decade high not seen since the dot-com era. The rise of special purpose acquisition companies (SPACs) in a market flush with liquidity has no doubt played a big part in the historic M&A spending figures. Goldman Sachs says 336 SPAC IPOs have raised $104 billion so far in 2021, adding to the $77 billion figure that blank-check firms raised in 2020. On top of that, the investment bank estimates there is still $118 billion of cash in 394 SPACs currently searching for an M&A target. Low interest rates, which have allowed for robust debt and equity issuance, have also pushed companies'' cash balances to record levels , meaning more M&A could be on the way. In a note to clients on Monday, Goldman analysts led by David J. Kostin predicted S&P 500 companies will spend $324 billion in cash M&A deals this year, a more-than 45% year-over-year increase.
   CRISPR Therapeutics AG Stock Is Estimated To Be Significantly Overvalued  2021/07/11 11:00:16 GuruFocus
Related Stocks: CRSP ,
   Crispr Therapeutics: Get Ready To Bail Out  2021/07/05 13:00:07 Seeking Alpha
   Crispr-Based Therapeutics Market Report 2021: Opportunities, Growth Factor, Trends, Share, Demand and Research Report Forecast to 2028 | Caribou Biosciences, Addgene, CRISPR THERAPEUTICS  2021/07/02 07:16:22 OpenPR
Crispr-Based Therapeutics Market report will provide one with overall market analysis, statistics, various trends, drivers, opportunities, restraints, and every minute data relating to the Synthetic Fibers market necessary for forecasting its revenue, factors propelling & growth. The Crispr-Based Therapeutics market
   Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer  2021/05/07 15:38:35 Benzinga
Nkarta Inc (NASDAQ: NKTX ) has collaborated with CRISPR Therapeutics AG (NASDAQ: CRSP ) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all the R&D costs and any worldwide … Full story available on
   Why CRISPR Therapeutics Stock Is Trading Higher Today  2021/04/26 19:52:04 Benzinga
CRISPR Therapeutics (NASDAQ: CRSP ) shares are trading higher after … Full story available on
   Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today  2021/04/26 18:18:28 Benzinga
Voyager Therapeutics, Inc. (NASDAQ: VYGR ), uniQure N.V. (NASDAQ: QURE ), Axsome Therapeutics, Inc. (NASDAQ: AXSM ), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCRSP) are among the biggest biotech movers in Monday's session. Voyager Gains On Lifting of Clinical Hold On Huntington's Disease Gene Therapy: Voyager, a gene therapy company developing treatments for severe neurological diseases, said the Food and Drug Administration has removed the clinical hold imposed on the company's investigational new drug application for VY-HTT01. VY-HTT01 is a gene therapy candidate that is being evaluated for the treatment of Huntington's disease. The FDA has communicated to the company that it can proceed with the planned Phase 1/2 study. The company said it plans to initiate the study this year. Voyager was jumping 20.13% to $5.61. uniQure Says Clinical Hold On Phase 3 Hemophilia Gene Therapy Study Removed: uniQure, a gene … Full story available on Benzinga.
   CRISPR Therapeutics Is Upgraded After $900 Million Deal  2021/04/21 12:10:00 Barron's
Jefferies analyst Maury Raycroft raised his rating on the stock to Buy from Hold and lifted his target for the share price to $172 from $165.
   Crispr Gets $900M From Vertex, Tied to Gene-Editing Therapy - TheStreet  2021/04/20 15:29:33 The Street
Crispr Therapeutics rose after it said it’s receiving $900 million from Vertex Pharma, a payment tied to a gene-editing therapy.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 CRISPRセラピュ―ティクス CRSP CRISPR Therapeutics AG)

 twitter  (公式ツイッターやCEOツイッターなど)